12 December 2013
NovaMedica LLC, ein russisches Pharmaunternehmen, und Venter Pharma SL, ein spanisches Unternehmen, das innovative diagnostische Systeme entwickelt, haben eine Partnerschaftsvereinbarung unterzeichnet, im Rahmen derer NovaMedica die Exklusivrechte erhält, um LacTEST®, eine neue Technologie für die Diagnose von Laktose-Intoleranz in Russland und der GUS (Gemeinschaft unabhängiger Staaten) zu vermarkten.
Venter Pharma y Novamedica, acuerdo de distribución de LacTest en Rusia
12 December 2013
LacTEST es un producto best-in-class de su categoría para el diagnóstico de la intolerancia a la lactosa en individuos de distintos grupos de edad. El test tiene aplicaciones en gastroenterología clínica y ha sido aprobado para su distribución en España y Alemania.
Venter Pharma and NovaMedica Sign Agreement to Commercialize New Lactose Intolerance Test in Russia
11 December 2013
NovaMedica LLC, a Russian pharmaceutical company, and Venter Pharma SL, a Spanish company, developing innovative diagnostic systems, have signed a partnership agreement that grants NovaMedica exclusive rights to commercialize a new technology for the diagnosis of lactose intolerance, LacTEST®, in Russia and the Community of Independent States (CIS).
06 December 2013
Das russische Pharmaunternehmen NovaMedica LLC hat eine Partnerschaftsvereinbarung mit dem führenden Hersteller von Spezialpharmazeutika, Aptalis Pharma, unterzeichnet, um innovative und wirksame Behandlungsoptionen für einen bislang ungedeckten medizinischen Bedarf bereitzustellen und drei der neuartigen gastrointestinalen Pharmaprodukte von Aptalis Pharma zu entwickeln und in Russland zu vermarkten.
06 December 2013
NovaMedica LLC, une société pharmaceutique russe, a signé un accord de partenariat avec Aptalis Pharma, une société pharmaceutique spécialisée de premier plan, qui fournit des thérapies novatrices efficaces répondant aux besoins médicaux non-satisfaits. Cet accord vise à développer et commercialiser, en Russie, un portefeuille de trois nouveaux produits pharmaceutiques d'Aptalis Pharma destinés au traitement des troubles gastrointestinaux.
NovaMedica to distribute Aptalis products in Russia
06 December 2013
Russian drugmaker NovaMedica has signed a partnership agreement with privately-held US firm Aptalis Pharma, to develop and commercialize a portfolio of three of Aptalis Pharma’s novel gastrointestinal pharmaceutical products in Russia. Under the agreement, financial terms of which were not disclosed, NovaMedica will work towards to completing the requirements for regulatory approval of the products in Russia. Subject to obtaining approvals, Aptalis’ pharmaceutical products are expected to come to market in 2014-2015.
NovaMedica, Aptalis Sign Russian Distribution Pact
06 December 2013
NovaMedica has signed a partnership agreement with Aptalis Pharma to develop and commercialize three of Aptalis' gastrointestinal products in Russia. The products include Pylera, indicated for the eradication of Helicobacter Pylori in patients with gastric or duodenal ulcer; Lacteol, a product derived from a human strain of Lactobacillus LB for use in patients with diarrhea; and Panzytrat, a formulation of pancreatic enzymes indicated for maldigestion due to exocrine pancreatic insufficiency related to cystic fibrosis, chronic pancreatitis, major pancreatic resection, gastric resection.
Kremlin seeks to monetise the field of science
17 October 2013
Change is coming to the 289-year-old Russian Academy of Sciences. Once famous for work that won it 18 Nobel Prizes and helped put the first man in space, the Academy has failed to keep up with the times.
NovaMedica Opens Plant in Russia
06 August 2013
Plant is part of local government’s strategy to develop pharmaceutical cluster.
RusnanoMedInvest invested in American technology for vision correction
02 August 2013
American venture Fund Domain Associates, venture investment company RusnanoMedInvest (RMI, affiliate of ROSNANO) and a group of co-investors invest $55M in the company ReVision Optics, Inc., which develops innovation medical technology for treatment of age-dependent visual acuity decrement.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia has expanded the mandatory health insurance program for 2024-2026
29 March 2024
Russian scientists have developed new TB vaccines for both injection and nasal administration.
29 March 2024
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024